Previous studies demonstrated that deletion of IL-22 suppressed diabetes progression led by autoreactive T cells [10], and that rmIL-22 treatment did not block streptozotocin-induced type 1 diabetes [11]. This evidence concerns the gene IL22 and type 1 diabetes mellitus.